Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer (vol 13, 3246, 2022)
R. C. Coombes,P. D. Badman,J. P. Lozano-Kuehne, X. Liu,I. R. Macpherson,I. Zubairi,R. D. Baird,N. Rosenfeld,J. Garcia-Corbacho,N. Cresti,R. Plummer,A. Armstrong, R. Allerton,D. Landers, H. Nicholas, L. McLellan, A. Lim,F. Mouliere,O. E. Pardo, V. Ferguson,M. J. Seckl NATURE COMMUNICATIONS（2023）
AI 理解论文
溯源树
样例
